SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is a focal point of discussion due to a congressional probe into its $500 million investment with an Abu Dhabi entity and its ongoing application for a National Trust Bank Charter. This has sparked intense debate, with some community members forecasting substantial growth from its forthcoming real-world asset platform and app, while others strongly denounce it as a fraudulent scheme.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after its swift decision to cease offering a compounded weight-loss pill following regulatory scrutiny and legal threats from major pharmaceutical companies. The community is divided, with some viewing it as a strategic de-risking move for its core telehealth business, while others criticize it as a major management blunder that damages trust and growth, amidst mixed reactions to its Super Bowl advertisement.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to widespread discussions surrounding a potential future merger involving SpaceX and xAI, alongside recent announcements about high-volume Semi production and significant investments in AI, robotics, and autonomous driving. This is fueling bullish outlooks for its long-term vision, though the community also expresses concerns about near-term profitability and ongoing controversies related to its CEO.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors eagerly await its BLA resubmission in February, a key step validated by the FDA's request for the full HOPE-3 clinical study report without additional trials. This development reinforces confidence in its Duchenne muscular dystrophy therapy and promising exosome platform amidst discussions of institutional interest.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following its recent acquisition and new financing designed to strengthen its HAE portfolio, yet community discussion remains largely negative, citing persistent stock undervaluation, increasing short interest, and perceived manipulation, further fueled by public comments from well-known financial personalities.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid a federal probe into alleged workplace discrimination and high anticipation for a Supreme Court ruling on tariffs that could impact its margins. While some in the community are betting on a strategic turnaround driven by new product innovation and North American growth, others remain skeptical, citing continued weakness in key markets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is highly active, driven by mixed semiconductor earnings and strong underlying commitments to massive AI infrastructure spending from big tech. Community discussion centers on whether this leveraged ETF presents a 'buy the dip' opportunity given the persistent AI narrative, or if it's forming a triple top around current levels, signaling a potential reversal.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is trending as strong Dupixent sales and recent pipeline breakthroughs in oncology and gene therapy are battling ongoing manufacturing delays for its Eylea HD pre-filled syringe at a third-party facility, prompting community discussion on the stock's undervaluation despite short-term volatility.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a recently announced $250 million financing amendment that extends its capital runway through 2028, fueling community speculation about a potential short squeeze and comparisons to its history of massive parabolic price movements. While many anticipate significant upward momentum, a notable counter-narrative raises concerns about potential dilution from the equity line of credit and the company's underlying profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat reports...

Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Sunday...

Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Hold"

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Saturday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. One...

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling...

Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Saturday...

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.read more...

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Hold" by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.34	--	--	N/A
Q3 '25	-$0.33	-$0.35	-4.80%	MISSED
Q2 '25	-$0.35	-$0.30	14.69%	BEAT
Q1 '25	-$0.29	-$0.35	-19.05%	MISSED
Q4 '24	-$0.32	-$0.62	-93.64%	MISSED

PYXS
Pyxis Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PYXS News

PYXSPyxis Oncology Inc